Literature DB >> 23213025

Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

Stephen J Polyak1, Peter Ferenci, Jean-Michel Pawlotsky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23213025      PMCID： PMC3594650          DOI： 10.1002/hep.26179

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  74 in total

1.  Acetaminophen hepatotoxicity in rats is attenuated by silybin dihemisuccinate.

Authors:  R Campos; A Garrido; R Guerra; A Valenzuela
Journal:  Prog Clin Biol Res       Date:  1988

2.  [Silymarin prevents peroxidation of lipids in carbon tetrachloride-induced liver damage].

Authors:  H M Rauen; H Schriewer; U Tegtbauer; J E Lasana
Journal:  Experientia       Date:  1973-11-15

3.  An adverse reaction to the herbal medication milk thistle (Silybum marianum). Adverse Drug Reactions Advisory Committee.

Authors: 
Journal:  Med J Aust       Date:  1999-03-01       Impact factor: 7.738

4.  Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.

Authors:  Sarah J Schrieber; Roy L Hawke; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Catherine M Meyers; Edward Doo; Michael W Fried
Journal:  Drug Metab Dispos       Date:  2011-08-24       Impact factor: 3.922

5.  Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy.

Authors:  U P Neumann; M Biermer; D Eurich; P Neuhaus; T Berg
Journal:  J Hepatol       Date:  2010-03-15       Impact factor: 25.083

Review 6.  Herbal modulation of P-glycoprotein.

Authors:  Shufeng Zhou; Lee Yong Lim; Balram Chowbay
Journal:  Drug Metab Rev       Date:  2004-02       Impact factor: 4.518

7.  Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.

Authors:  Roy L Hawke; Sarah J Schrieber; Tedi A Soule; Zhiming Wen; Philip C Smith; K Rajender Reddy; Abdus S Wahed; Steven H Belle; Nezam H Afdhal; Victor J Navarro; Josh Berman; Qi-Ying Liu; Edward Doo; Michael W Fried
Journal:  J Clin Pharmacol       Date:  2009-10-19       Impact factor: 3.126

8.  Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.

Authors:  Zhiming Wen; Todd E Dumas; Sarah J Schrieber; Roy L Hawke; Michael W Fried; Philip C Smith
Journal:  Drug Metab Dispos       Date:  2007-10-03       Impact factor: 3.922

Review 9.  An updated systematic review of the pharmacology of silymarin.

Authors:  Reinhard Saller; Jörg Melzer; Jürgen Reichling; Reto Brignoli; Remy Meier
Journal:  Forsch Komplementmed       Date:  2007-04-23

10.  Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Authors:  Abdelhakim Ahmed-Belkacem; Nazim Ahnou; Laetitia Barbotte; Czeslaw Wychowski; Coralie Pallier; Rozenn Brillet; Ralf-Torsten Pohl; Jean-Michel Pawlotsky
Journal:  Gastroenterology       Date:  2009-12-04       Impact factor: 22.682
View more
  29 in total

1.  Chemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.

Authors:  Brandon T Gufford; Tyler N Graf; Noemi D Paguigan; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-08-27       Impact factor: 3.922

2.  In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin.

Authors:  Ebru Evren; Erkan Yurtcu
Journal:  Folia Microbiol (Praha)       Date:  2015-05-04       Impact factor: 2.099

3.  Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

Authors:  S DebRoy; N Hiraga; M Imamura; C N Hayes; S Akamatsu; L Canini; A S Perelson; R T Pohl; S Persiani; S L Uprichard; C Tateno; H Dahari; K Chayama
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

4.  Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling.

Authors:  Erica S Lovelace; Jessica Wagoner; James MacDonald; Theo Bammler; Jacob Bruckner; Jessica Brownell; Richard P Beyer; Erika M Zink; Young-Mo Kim; Jennifer E Kyle; Bobbie-Jo M Webb-Robertson; Katrina M Waters; Thomas O Metz; Federico Farin; Nicholas H Oberlies; Stephen J Polyak
Journal:  J Nat Prod       Date:  2015-07-17       Impact factor: 4.050

5.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

6.  Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism.

Authors:  Janela McClure; Daciana H Margineantu; Ian R Sweet; Stephen J Polyak
Journal:  Virology       Date:  2013-11-27       Impact factor: 3.616

7.  Complementary and Alternative Medicine Use in United States Adults With Liver Disease.

Authors:  Jacqueline B Henson; Cristal L Brown; Shein-Chung Chow; Andrew J Muir
Journal:  J Clin Gastroenterol       Date:  2017-07       Impact factor: 3.062

Review 8.  Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer.

Authors:  Jessica Brownell; Stephen J Polyak
Journal:  Clin Cancer Res       Date:  2013-01-15       Impact factor: 12.531

9.  Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle.

Authors:  Hanan S Althagafy; Tyler N Graf; Arlene A Sy-Cordero; Brandon T Gufford; Mary F Paine; Jessica Wagoner; Stephen J Polyak; Mitchell P Croatt; Nicholas H Oberlies
Journal:  Bioorg Med Chem       Date:  2013-04-16       Impact factor: 3.641

10.  Uncovering biologically significant lipid isomers with liquid chromatography, ion mobility spectrometry and mass spectrometry.

Authors:  Jennifer E Kyle; Xing Zhang; Karl K Weitz; Matthew E Monroe; Yehia M Ibrahim; Ronald J Moore; Jeeyeon Cha; Xiaofei Sun; Erica S Lovelace; Jessica Wagoner; Stephen J Polyak; Thomas O Metz; Sudhansu K Dey; Richard D Smith; Kristin E Burnum-Johnson; Erin S Baker
Journal:  Analyst       Date:  2016-03-07       Impact factor: 4.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.